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Abstract Plasminogen (PC), urokinase-type plasminogen acti- 
vator (u-PA) and tissue-type PA (t-PA) are the main molecules 
involved in fibrinolysis and in many other physiological and pa- 
thological processes. In the present study we report that human 
t-PA, purified from human melanoma cells, and PG, purified 
from human plasma, both contain P-Tyr residues, as revealed by 
immunoblotting analyses with monoclonal anti-P-Tyr antibodies. 
In addition HPLC amino acid analysis of acid-hydrolyzed t-PA, 
PG and u-PA, shows that: (i) P-Ser and P-Tyr residues are 
present in t-PA; (ii) P-Thr and P-Tyr are present in PG; (iii) 
P-Ser, P-Thr and P-Tyr are present in u-PA. The utilization of 
monoclonal anti-P-Ser and anti-P-Thr antibodies in immunoblot- 
ting experiments has confirmed these data which indicate that 
phosphorylation is a common feature of PAS and of PG. 
Key words: Human tissue-type plasminogen activator; 
Urokinase-type plasminogen activator; Human plasminogen; 
Phosphorylation 
1. Introduction 
Plasminogen (PG), tissue-type plasminogen activator (t-PA) 
and urokinase-type PA (u-PA) are involved in the plasmin- 
generating system, one of the physiological proteolytic machin- 
eries utilized by tissues and cells to generate localized and direc- 
tional proteolysis [1,2,3]. Activation of Glu-plasminogen (791 
amino acids) to the active enzyme [4] occurs through cleavage 
of Args6’ -Va156’ peptide bond, near the carboxyl-terminal end 
of ‘kringle’ 5 (K5), by PAS. u-PA and t-PA are serine proteases 
[3,5] secreted as single chain proteins (set-PA and scu-PA) 
which are cleaved by plasmin giving rise to two chain t-PA and 
to two chain u-PA respectively (tct-PA, tcu-PA) [5,6]. PG, t-PA 
and u-PA structures have in common ‘kringle’ modules [7], 
specialized for protein binding, and the carboxyl-terminal re- 
gion, homologous to the catalytic domain of other serine-pro- 
teases, such as prothrombin and trypsin. In addition, PG and 
t-PA interact with fibrin [S], with fibronectin and its degrada- 
tion products [9,10] and t-PA is able to promote transformation 
in vitro [ll]. Recently much attention has been given to the 
phosphorylation of u-PA which might confer specific biological 
properties to the enzyme [12-171. This paper reports evidences, 
obtained by immunoblotting and HPLC amino acid analysis, 
of the phosphorylation of Ser and Tyr residues in t-PA, of Thr 
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and Tyr residues in PG and of Ser, Thr and Tyr residues in 
u-PA. 
2. Materials and methods 
2.1. Materials 
Human set-PA (EC 3.4.21) with specific activity of 634,000 IU/mg, 
from cultured human melanoma cells, and human Glu-PG from pooled 
human plasma were purchased from Biopool (Umea, Sweden); human 
tcu-PA (EC 3.4.21.31) with snecific activitv of 92.719 IU/ma was nur- 
chased from Serva (Heidelberg, Germany) and human recombinant 
t-PA (rt-PA, 0.58 MIU/mg), produced in animal cells, was purchased 
from Boehringer Ingelheim. The purity of t-PA, u-PA and PG was 
ascertained by electrophoretic mobility, enzymatic assays and selective 
inhibition studies. 
O-Phospho-oL-serine, O-phospho-m-threonine, O-phospho-m-ty- 
rosine, low molecular weight markers and the monoclonal anti-P-Ser 
and anti-P-Thr antibodies (MoAb) [18], provided as mouse ascites 
fluids, were from Sigma (St. Louis, MO, USA). 
Goat anti-human t-PA IgGs were from Biopool (Umea, Sweden); 
rabbit anti-human PG was from Dako (Denmark). The rabbit polyclo- 
nal affinity-purified anti-P-Tyr IgG were kindly provided by Dr. Wang 
(San Diego, La Jolla, CA, USA) [19] and were also purchased from UBl 
(NY, USA); the anti-P-Tyr MoAb were obtained culturing the lG2 
hybridoma cells [20] obtained from ATCC (USA) with the permission 
of Dr. Frackelton (Providence, RI, USA); the f-42 monoclonal antibod- 
ies against the N-terminal end of human plasma fibronectin were ob- 
tained as previously described [21]. Alkaline phosphatase (AP)-conju- 
gated rabbit anti-goat, goat anti-rabbit and anti-mouse IgG, were from 
Promega (W 153711, USA), as well as the Nitroblue tetrazolium (NBT) 
and 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) substrates. 
Acetonitrile, triethylamine (TEA), phenylisothiocyanate and amino 
acid standards (Pierce H) were from Waters Assoc., while Sequanol 
grade hydrochloric acid was from Pierce (Rockville, IL, USA). 
2.2. NuDodSo4-polyacrylamide gel electrophoresis 
Polyacrylamide gel electrophoresis (PAGE) in the presence of so- 
dium-dodecyl-sulphate (SDS), was performed according to Laemmli 
[22] using vertical slab gels. The acrylamide concentrations were 3.3% 
in the stacking gel and 8% in the running one. The samples were diluted 
in Laemmli’s sample buffer in the ratio of 1: 1 (v/v). 
2.3. Zymographic procedure and immunoblotting of proteins 
Zymography of proteins was carried out by a procedure developed 
by Colombi et al. [23]. The proteins were separated by 8% PAGE in the 
presence of SDS under non-reducing conditions and electrotransferred 
on nitrocellulose sheets (Scleicher & Schtill, Germany) according to 
Laemmli and Towbin, respectively [22,24]. After transfer, the filters 
were overlaid onto casein plates containing 2 &ml of human plasmin- 
ogen. The lysis bands, developed after 24 h of incubation at 37°C in 
humidified atmosphere, were photographed using dark-field light. In 
immunoblotting experiments, after transfer and saturation, the filters 
were incubated overnight at room temperature with the first antibody 
which, depending on the experiments, were: goat anti-human t-PA or 
rabbit anti-human PG (1: 500, v/v), polyclonal affinity-purified anti-P- 
Tyr antibodies (0.3 pg/ml), lG2 monoclonal anti-P-Tyr antibodies 
(1: 25, v/v), monoclonal anti-P-Ser or anti-P-Thr antibodies 
(1: 10,000, 1: 100, v/v, respectively), f-42 monoclonal anti-FN antibod- 
ies (5 pg/ml). After washing, the filters were incubated with AP-conju- 
gated rabbit anti-goat IgG or goat anti-rabbit IgG (1 : 1,000, v/v) or 
goat anti-mouse IgG (1: 7,500, v/v) and the positive bands evidenced 
with NBT and BCIP substrates [25]. 
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2.4. Acid hydrolysis of proteins and derivatization of amino acids with 
PITC 
Four sample tubes (6 x 50 mm), each containing 50 or lOOpug of t-PA, 
PG or u-PA, were placed in a reaction vial and vacuum-dried using the 
PICO-TAG Work Station [26]. 200 ~1 of concentrated HCl (37%) and 
one phenol crystal was added at the bottom of the reaction vial; this 
reaction vial was purged alternately with nitrogen and after final evac- 
uation to remove O,, its valve was closed, and the reaction vial itself 
heated in Work Station oven at 106°C for 7 h, subsequently cooled and 
vacuum-dried to remove excess HCl. 20 ,~l of the redry solution (etha- 
nol-water-triethylamine TEA, 2 : 2 : 1 v/v) were added to each sample 
tube, which was then vacuum-dried. 10 ,uI of the derivatizing solution 
(ethanol/water/triethylamine/phenylisothiocyanate: 7 : 1 : 1: 1, v/v) were 
added to each sample and the tubes were placed in the reaction vial and 
let stand at room temperature for 10 min; each sample was dried under 
vacuum and dissolved in 200 ~1 of sample diluent [27]. 
2.5. HPLC analyses 
The acid-hydrolyzed preparations of amino acids and of the proteins 
(t-PA or PC or u-PA) after derivation were submitted to HPLC amino 
acid analysis. Separation of the amino acids was achieved using a 
Waters PICO-TAG reverse phase column (free amino acid analysis 
column, 3.9 mm x 300 mm, cod. 10950 Waters, two pumps Mod. 510, 
Waters, programmed gradient Mod. 680) and a method (developed in 
Waters’ Chicago laboratory) which allows to separate the phospho- 
amino acids by reducing the concentration of acetonitrile in the initial 
buffer. The eluents utilized were, eluent A (140 mM NaOAc, pH 6.4; 
0.5 ml TEA/I) and eluent B (60% acetonitrile in water). 
3. Results 
3.1. Tyrosine phosphorylation of purtjied t-PA and PG 
Aliquots of t-PA, from human melanoma cells, or of PG, 
from human plasma (Fig. lA,B: from lanes 1-8) were electro- 
phoresed in 8% SDS-PAGE under non-reducing conditions. 
After electrotransfer on nitrocellulose filters, portions of the 
filters were amido black-stained (lanes 1), immunoreacted with 
polyclonal anti-t-PA (Fig. lA, lane 2) or anti-PG antibodies 
(Fig. lB, lane 2), with monoclonal anti-P-Tyr antibodies in the 
absence (lanes 3) or in the presence of 20 mM P-Tyr (lanes 4) 
or 20 mM P-Ser, P-Thr (lanes 6 and 7, respectively) and with 
the secondary AP-conjugated goat anti-mouse antibodies as 
control (lanes 4). Zymographic analysis of t-PA is reported in 
lane 8. 
In the case of t-PA, the 70 kDa molecule evidenced by amido 
black and by anti-t-PA (Fig. lA, lanes 1 and 2, respectively) was 
also recognized by anti-P-Tyr MoAb (Fig. lA, lane 3). 
Similarly, for PG, the 90 kDa stained protein band reacted 
with anti-PG antibodies and with anti-P-Tyr MoAb. In both 
cases, the immunological recognition by anti-P-Tyr antibodies 
was inhibited by the addition of 20 mM P-Tyr, but not by 20 
mM of P-Ser or P-Thr (lanes 5, 6 and 7). In addition to anti- 
P-Tyr MoAb, also polyclonal anti-P-Tyr antibodies were used 
in immunoblotting experiments, with similar results, as it has 
been reported for Tyr-phosphorylation of u-PA [ 131. It has also 
Table 1 
Comparison of the amino acid standards analyzed in HPLC 
A 1 2 34567 8 
B 12 34567 8 
Fig. 1. Tyrosine phosphorylation of purified human t-PA and PG. 
Aliquots of t-PA, purified from cultured human melanoma cells and of 
PG, purified from human plasma, were electrophoresed and transferred 
on nitrocellulose filters (panels A and B, respectively). The single lanes 
were separated, stained with Amido black (lanes 1), incubated with 
polyclonal anti-t-PA or anti-PG antibodies (lanes 2, A and B, respec- 
tively), with monoclonal anti-P-Tyr antibodies in the absence (lanes 3, 
A and B) or in the presence of 20 mM P-Tyr (lanes 5, A and B) or 20 
mM P-Ser, P-Thr (lanes 6 and 7, respectively, A and B); lanes 4 (A and 
B) refer to the t-PA and to the PG incubated only with AP-conjugated 
goat anti-mouse antibodies; lane 8 (panel A) refers to the zymographic 
analysis of t-PA; lanes 9 and 8 (A and B) refer to t-PA and PG incubated 
in the presence of f-42 anti-FN MoAb. Aliquots of 0.3 pg of t-PA were 
loaded in lanes 2 and 8 and of 5 pg in lanes 1, 3,4, 5, 6, 7 and 9 (panel 
A). Aliquots of 0.3 and 5 pg of PC were loaded in tracks 2 and 1, 3, 
5, 6, 7. 8, respectively (panel B). 
been verified that phospho-amino acids did not interfere with 
immunological recognition of t-PA, PG and u-PA with other 
antibodies (not shown). 
3.2. HPLC based phospho-amino acid analysis of t-PA and PG 
Fig. 2 (panels A and B) reports the relevant portions of the 
HPLC chromatograms of the amino acid standards before and 
after hydrolysis, respectively. As reported in Table 1 the recov- 
ery of phospho-amino acids after acid hydrolysis was: 37.1% 
for P-Ser, 89.1% for P-Thr and 13.8% for P-Tyr. Fig. 3 reports 
the analysis of the acid hydrolysis of 10 pug of each protein; 
panel A, B and C refer to t-PA (143 pmol), PG (111 pmol) and 
u-PA (182 pmol), respectively. The analysis revealed the pres- 
ence of P-Tyr residues in t-PA, PG and u-PA, of P-Ser residues 
in both PAS and of P-Thr residues in PC and u-PA. The 
Retention time Peak area Loaded (pmol) Recovered 
(min) 





P-Thr 4.37 370,422 500 500 100 
P-Tyr 5.82 398,65 1 500 500 100 
Acid hydrolyzed amino acids P-Ser 3.39 187,295 1000 371 37.1 
P-Thr 4.35 660,124 1000 891 89.1 
P-Tyr 5.83 110,705 1000 138 13.8 
172 
A 
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Fig. 2. HPLC analysis of amino acid standards. Panel A refers to the not-hydrolyzed and panel B to the acid-hydrolyzed amino acid standards. Panel 
A: 500 and 1,250 pmol of phosphorylated and not phosphorylated amino acids were respectively loaded for HPLC analysis. Panel B: twice the amounts 
reported in panei A. Valnes given are peak retention times in minutes 
phospho-amino acids concentration corresponding to the 
peaks detected by this analysis has been directly evaluated by 
the computerized system associated to the HPLC apparatus 
taking into account the recovery of phospho-amino acids after 
hydrolysis (see Table 1); the pmol obtained were the following: 
145, 77 and 105 for P-Tyr in t-PA, PG and u-PA, respectively; 
141 and 50 for P-Ser in t-PA and in u-PA; 128 and 95 for P-Thr 
in PG and in u-PA (Table 2). 
u-PA reacted with anti-P-Ser MoAb (lanes 1 and 5, respec- 
tively); PG and u-PA reacted with anti-P-Thr MoAb (lanes 3 
and 6, respectively) and incubation with the secondary anti- 
body did not give any signal for t-PA, PG and u-PA (lanes 2, 
4 and 7, respectively). 
The concentration of protein hydrolyzate was evaluated 
from the average percentage yield of the different amino acids 
obtained from each protein and compared to the respective 
number of amino acid residues present in each molecule. As 
reported in Table 2, the amount of acid hydrolyzed proteins 
were: 76% for t-PA (1091143 pmol), 73% for PG (81/l 11 pmol) 
and 84% for u-PA (153/182 pmol). 
In control experiments, the anti-fibronectin monoclonal anti- 
body f-42 (see Figs. 1 and 4), as well as control mouse IgG (not 
shown), did not evidence any positive signal when tested 
against t-PA and PG (Fig. 1, panels A and B, lanes 9 and 8) 
and against u-PA (Fig. 4, lane 8). 
4. Discussion 
Considering the ratio between P-amino acid pmol and hydro- 
lyzed protein pmol, the results obtained suggest that only a 
limited number (1 or 2) of the Ser, Thr and Tyr out of those 
present in the proteins are susceptible to phosphorylation. The 
results obtained are in line with those obtained by Mastronicola 
et al. [12] in the case of P-Ser of u-PA where two phosphoryla- 
tion sites have been demonstrated. 
Recent studies, performed in our [ 131 and other laboratories 
[12,14-171, have shown that human urokinase-type PA can be 
phosphorylated in Tyr and/or Ser residues. In this paper, we 
have shown by two different approaches, HPLC and im- 
munoblotting, that both PAS contain P-Ser residues, that u-PA 
and PG contain P-Thr residues and that, in addition to u-PA, 
also t-PA and PG contain P-Tyr residues. 
3.3. Immunological recognition of P-Ser and P-Thr residues in 
t-PA, PG and u-PA 
The P-Ser and the P-Thr residues detected by HPLC analysis 
were also immunologically recognized by monoclonal anti-P- 
Ser and anti-P-Thr antibodies (Fig. 4). As expected, t-PA and 
The computer search of phosphorylation consensus se- 
quences [28], present in these molecules, evidenced several con- 
sensus sequences for phosphorylation by SerlThr kinases (cy- 
clic nucleotide-dependent protein-kinase, casein-kinase II and 
protein kinase C) in the domains of PAS and of PG except for 
the finger domain of t-PA; in particular, 13 sequences have been 
evidenced in u-PA, 17 in t-PA and 22 in PG. Considering the 
Tyr-phosphorylation consensus sequences KIW)x(2,3) 
Table 2 
Summary of the data obtained by HPLC phospho-amino acid analysis of t-PA, PG and u-PA. 
Loaded protein Phospho-amino acids Hydrolyzed protein P-amino acids (pmol) 
(pmol) % pm01 Hydrolyzed protein (pmol) 
t-PA 10 pug/143 pmol P-Ser 141 16 109 1.30 
P-Tyr 145 1.33 
PG 10 ,&lll pmol P-Thr 128 73 81 1.58 
P-Tyr II 0.95 
u-PA 10 pug/182 pmol P-Ser 50 84 153 0.32 
P-Thr 95 0.62 
P-Tvr 105 0.68 
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Fig. 3. HPLC-based phospho-amino acid analysis of acid-hydrolyzed t-PA, PG and u-PA (panel A, B and C, respectively). Values given are peak 
retention times in minutes: P-Ser, 3.29 and P-Tyr, 5.80 for t-PA (panel A); P-Thr, 4.28 and P-Tyr, 5.80 for PG (panel B); P-Ser, 3.18, P-Thr, 4.30 
and P-Tyr. 5.80 for u-PA (panel C). The pmoles values corresponding to the peak areas have been directly evaluated by the computerized system 
of the HPLC apparatus taking into account the recovery of each phospho-amino acid of the acid hydrolyzed standard preparation (see the text, Tables 
1 and 2) 
(D,E)x(2,3)Y, (K)x(2)(D)x(3)Y], only one is present in the pro- 
teolytic domain of u-PA, (amino acids 21 l-218), t-PA (amino 
acids 396403) and of PG (amino acids 504-511) and other two 
are present in the first and in the fifth kringle of PG (amino 
acids 84-91 and 298-304, respectively). In the case of u-PA, 
these data are consistent with those, previously reported [13], 
which showed the presence of Tyr-phosphorylation in the pro- 
teolytic domain of the 33 kDa mini-two chain u-PA. 
From the quantitative analysis on the level of phosphoryla- 
tion obtained by HPLC, it can be concluded that only a limited 
number (1 or 2) of the Ser and Thr residues, present in the 
molecules analyzed, should be susceptible to phosphorylation 
in agreement with previous data on Ser-phosphorylation of 
u-PA molecules secreted by tumor cells [12]. 
The data reported open the questions not only on the biolog- 
ical significance of phosphorylation of these molecules, but also 
on the kinases responsible for the phosphorylation of these 
secreted proteins. 
A B C 
12 34 567 8 
Fig. 4. Immunoblotting analysis of PG and PAS for the evaluation of 
P-Ser and P-Thr residues. Aliquots of human t-PA, PG and u-PA were 
analysed by immunoblotting with monoclonal anti-P-Ser and anti-P- 
Thr antibodies. Panel A, lane 1, refers to t-PA (5 pg) reacted with 
anti-P-Ser antibodies, panel B, lane 3 refers to PG (5 pg) reacted with 
anti-P-Thr antibodies; panel C, lanes 5 and 6, refer to u-PA (2 pg) 
reacted with anti-P-Ser and anti-P-Thr antibodies, respectively; lanes 
2, 4 and 7 refer to t-PA (5 pug), PG (5 pg) and u-PA (2 pg) reacted as 
control only with the secondary antibodies; lane 8 refers to u-PA (2 pg) 
reacted with the f-42 anti-FN MoAb. 
Concerning the role of phosphorylation, it has been previ- 
ously shown that phosphorylation of u-PA decreases its affinity 
with PA inhibitors (PA1 type 1 and 2), thus indirectly increasing 
the urokinase enzymatic activity (12, 1416) which might fa- 
vour the invasive properties of tumor cells. 
In this line, Tyr and Ser phosphorylation of u-PA has been 
shown to be associated respectively with the activation of 
pp60src and of protein kinase C in metastatic [14] and in tumor 
cells [ 12,161. In addition a shift in the isoelectric point of u-PA 
(from 9.2 to 7.6), likely associated with phosphorylation, has 
been reported as a function of tumor growth in the plasma of 
Balb/C mice injected with metastatic murine cells [23]. 
Concerning phosphorylation of secreted proteins (i.e. osteo- 
pontin, IGFBP-1, fibrinogen, [29]), this might occurr via intra- 
cellular or extracellular kinases, as it has been shown in the case 
of the p amyloid precursor protein, whose phosphorylation 
may be due to the luminal kinases present in the central vacu- 
olar pathway [30] or to ecto-protein kinases present in the 
extracellular compartment [31,32]. No data, however, are avail- 
able on the kinases involved in t-PA, PG and u-PA phosphoryl- 
ation and on its role on the multiple biological functions exerted 
by these proteins. 
In particular we are interested in verifying the possible role 
of phosphorylation in relationship with their PG-independent 
enzymatic activities [10,33,34] and mitogenic effect exerted on 
human fibroblasts [35], also considering the interaction with PA 
receptors and inhibitors. 
Acknowledgements: We thank Dr. A. Scandroglio and Mr. P. Nebuloni 
(Waters Division, Milano, Italy) for support in HPLC analysis and 
Mrs. B. Arici for skilful technical assistance. This work was supported 
by grants awarded by C.N.R. Target Projects C.N.R., ‘Clinical Appli- 
cations of Oncology’, ‘Biotechnology and Bioinstrumentation’, ‘Ge- 
netic Engineering’, by A.I.R.C. and by M.U.R.S.T. 
References 
[l] Dano, K., Andreasen, P.A., Grondahl-Hansen, J., Kristensen, P., 
Nielsen, L.S. and Skrives, L. (1985) Adv. Cancer Res. 44, 140-266. 
174 S. Barlati et ai.IFEBS Letters 363 (199.5) 170-174 
21 Saksela, 0. and Rifkin, D. (1988) Annu. Rev. Cell. Biol. 4,93-126. 
31 Laiho, M. and Keski-Oja, J. (1989) Cancer Res. 49, 2533-2553. 
41 Jensen, L.S., Claeys, H., Zajdel, M., Petersen, T.E., Magnusson, 
S. (1978) in: Fibrinolysis (Davidson, J.F., Rowan, R.M., Samana, 
M.M. and Desnoyers, P.C. eds.) The Primary Structure of Human 
Plasminogen: Isolation of Two Lysine-Binding Fragments and 
One Mini-Plasminogen (MW 38000) by Elastase-Catalyzed-Spe- 
cific Limited Proteolysis, vol. 3, New York, Raven Press, pp. 
191-209. 
[5] Harris Jr., T. (1987) Protein Eng. 1, 6, 449458. 
161 Riiken. D. and Collen. D. (1981) J. Biol. Chem. 256. 7035-7041. 
[‘7j Patthy; L. (1985) Cell 41, 6577663. 
[8] Van Zonnerveld, A.J., Veerman, H. and Pannekoek, H. (1986) 
J. Biol. Chem. 261, 1421414218. 
[9] Salonen, E.M., Saksela, O., Vartio, T., Vaheri, A., Nielsen, L.S. 
and Zeuthen, J. (1985) J. Biol. Chem. 260, 12302-12307. 
[lo] Marchina, E., De Petro, G. and Barlati, S. (1993) Fibrinolysis 7, 
51-57. 
[ll] De Petro, G., Vartio, T., Salonen, E.M., Vaheri, A. and Barlati, 
S. (1984) Int. J. Cancer 33, 563-567. 
[12] Mastronicola, M.R., Stoppelli, M.P., Migliaccio, A., Auricchio, F. 
and Blasi. F. (1990) FEBS Lett. 266. 1099114. 
[13] Barlati, S:, Paracini, F., Bellotti, D. and De Petro, G. (1991) FEBS 
Lett. 281, 1377140. 
[14] Takahashi, K., Kwaan, C.H., Ikeo, K. and Koh, E. (1992) Bio- 
them. Biouhvs. Res. Commun. 182. 14661472. 
[15] Takahashc K., Kwaan, H.C., Koh, E. and Tanabe, M. (1992) 
Biochem. Biophys. Res. Commun. 182, 147331481. 
[16] Mastronicola, M.R., France, P., De Cesare, D., Massa, A. and 
Stoppelli, M.P. (1992) Fibrinolysis 4, 117-120. 
1171 France, P., Mastronicola, M.R., De Cesare, D., Nolli, M.L., Wun, 
T.C., Verde, P., Blasi, F. and Stoppelli, M.P. (1992) J. Biol. Chem. 
267, 19369-19372. 
[18] Levine, I., Gjika, B.H. and Van Vunakis, H. (1989) J. Immunol. 
Methods 124, 239-249. 
[19] Wang, J.Y. (1985) Mol. Cell. Biol. 5, 364%3643. 
[20] Frackelton, A.R., Posner, M., Kannan, B. and Mermelstein, F. 
(1991) Methods Enzymol. 201, 79-93. 
[21] Vartio, T., Salonen, E., De Petro, G., Barlati, S., Miggiano, V., 
Stahli C., Virgallita G., Takacs B. and Vaheri, A. (1983) Biochem. 
J. 215, 1477151. 
[22] Laemmli, U.K. (1970) Nature 227, 680-685. 
1231 Colombi. M.. Rebessi. L.. Boiocchi. M. and Barlati. S. (1986) 
L  1  
Cancer Res. 46, 574885753. 
~ I 
[24] Towbin, H., Staehelin, T. and Gordon, J. (1979) Proc. Natl. Acad. 
Sci. USA 76, 435%4354. 
[25] Leary, J., Brigatti, J. and Ward, D. (1983) Proc. Natl. Acad. Sci. 
USA 80, 40454049. 
[26] Budde, J.A.R., Holbrook, G.P. and Chollet, R. (1985) Arch. Bio- 
them. Biophys. 242, 2833290. 
[27] Bidlingmejer, B.A., Cohen, S.A. and Tarvin, T. (1984) J. Chroma- 
togr. 336, 93-104. 
[28] Pinna, L., Agostinis, P. and Ferrari, S. (1986) Adv. Prot. 
Phosphatases III 3277368. 
[29] Jones, J.I., D’Ercole, A.J., Camacho-Hubner, C. and Clemmens, 
D.R. (1991) Proc. Natl. Acad. Sci. USA 88, 7481-7485. 
[30] Knops, J., Gandy, S., Greengard, P. and Lieberburg, I. (1993) 
Biochem. Biophys. Res. Commun. 197, 380-385. 
[31] Ehrlich, Y.H., Davis, T.B., Bock, E., Kornecki, E. and Lenox, 
R.H. (1986) Nature 320, 67-70. 
[32] Hung A.Y. and Selkoe, D. (1994) EMBO J. 13, 534542. 
[33] Barlati, S. (1994) in: Forum on Metastasis, Bulletin de I’Institut 
Pasteur, Paris, (R.M. Fauve ed.) Plasminogen Activators and Fi- 
bronectin Fragments in Tumor Growth and Signal Transduction, 
vol. 92, no. 4, pp. 4147. 
[34] Gold, L., Rostagno, A., Frangione, B. and Passalaris. T., (1992) 
J. Cell. Biochem. 50, 441448. 
[35] De Petro, G., Copeta, A. and Barlati, S. (1994) Exp. Cell Res. 213, 
286294. 
